Pharmacy and Therapeutics Committee
"Pharmacy and Therapeutics Committee" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advisory group composed primarily of staff physicians and the pharmacist which serves as the communication link between the medical staff and the pharmacy department.
| Descriptor ID |
D010606
|
| MeSH Number(s) |
N04.452.758.788.682 N05.700.685.625
|
| Concept/Terms |
Committee, Drug- Committee, Drug
- Drug Committees
- Drug Committee
- Committee, Formulary
- Committees, Formulary
- Formulary Committees
- Formulary Committee
- Committee, Pharmacy
- Committees, Pharmacy
- Pharmacy Committee
- Pharmacy Committees
- Committee, Therapeutics
- Committees, Therapeutics
- Therapeutics Committees
- Therapeutics Committee
- Committees, Drug
|
Below are MeSH descriptors whose meaning is more general than "Pharmacy and Therapeutics Committee".
Below are MeSH descriptors whose meaning is more specific than "Pharmacy and Therapeutics Committee".
This graph shows the total number of publications written about "Pharmacy and Therapeutics Committee" by people in this website by year, and whether "Pharmacy and Therapeutics Committee" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacy and Therapeutics Committee" by people in Profiles.
-
Report of the 2019-2020 AACP Academic Affairs Committee: Developing the Pharmacist Workforce for Society's Medication Use Needs in 2030. Am J Pharm Educ. 2020 10; 84(10):ajpe8203.
-
Advancing Our Pharmacy Reformation - Accelerating Education and Practice Transformation: Report of the 2019-2020 Argus Commission. Am J Pharm Educ. 2020 10; 84(10):ajpe8205.
-
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1726-36.
-
The case for a value-based formulary: striving for total lowest net cost. Manag Care Interface. 2007 Apr; 20(4):42-7.
-
Who should receive antiendotoxin monoclonal antibody therapy? Clin Pharm. 1992 Mar; 11(3):255-6.
-
Impact of a pharmacist/physician cooperative target drug monitoring program on prophylactic antibiotic prescribing in obstetrics and gynecology. Hosp Pharm. 1992 Mar; 27(3):213-6.
-
Rational formulary selection of antimicrobials. Am J Hosp Pharm. 1987 Jan; 44(1):74.